Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Sockel K, Götze K, Ganster C, Bill M, Georgi JA, Balaian E, Aringer M, Trautmann-Grill K, Uhlig M, Bornhäuser M, Haase D, Thiede C. Sockel K, et al. Among authors: bill m. Ann Hematol. 2024 Mar;103(3):993-997. doi: 10.1007/s00277-023-05611-w. Epub 2024 Jan 12. Ann Hematol. 2024. PMID: 38214707 Free PMC article.
Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.
Wurm AA, Brilloff S, Kolovich S, Schäfer S, Rahimian E, Kufrin V, Bill M, Carrero ZI, Drukewitz S, Krüger A, Hüther M, Uhrig S, Oster S, Westphal D, Meier F, Pfütze K, Hübschmann D, Horak P, Kreutzfeldt S, Richter D, Schröck E, Baretton G, Heining C, Möhrmann L, Fröhling S, Ball CR, Glimm H. Wurm AA, et al. Among authors: bill m. Cell Rep Med. 2023 Oct 17;4(10):101200. doi: 10.1016/j.xcrm.2023.101200. Epub 2023 Sep 20. Cell Rep Med. 2023. PMID: 37734378 Free PMC article.
Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TP, Merz M, Franke GN, Metzeler KH, Vucinic V, Herling M, Platzbecker U, Jentzsch M. Schwind S, et al. Among authors: bill m. Hemasphere. 2024 Mar 18;8(3):e55. doi: 10.1002/hem3.55. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38501048 Free PMC article. No abstract available.
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M. Bischof L, et al. Among authors: bill m. Leukemia. 2024 Jan;38(1):198-201. doi: 10.1038/s41375-023-02072-y. Epub 2023 Oct 25. Leukemia. 2024. PMID: 37880479 Free PMC article.
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DWL, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SEW, Woll PS, Olweus J. Giannakopoulou E, et al. Among authors: bill m. Nat Cancer. 2023 Oct;4(10):1474-1490. doi: 10.1038/s43018-023-00642-8. Epub 2023 Oct 2. Nat Cancer. 2023. PMID: 37783807 Free PMC article.
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Eckardt JN, et al. Among authors: bill m. Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7. Leukemia. 2023. PMID: 37679502 Free PMC article. No abstract available.
Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
Neldeborg S, Soerensen JF, Møller CT, Bill M, Gao Z, Bak RO, Holm K, Sorensen B, Nyegaard M, Luo Y, Hokland P, Stougaard M, Ludvigsen M, Holm CK. Neldeborg S, et al. Among authors: bill m. Leukemia. 2023 Sep;37(9):1792-1801. doi: 10.1038/s41375-023-01950-9. Epub 2023 Jul 18. Leukemia. 2023. PMID: 37464068 Free PMC article.
114 results